Log in

LON:CIRCircassia Pharmaceuticals Share Price, Forecast & News

GBX 27.90
-0.03 (-0.11 %)
(As of 08/13/2020 04:06 AM ET)
Today's Range
Now: GBX 27.90
50-Day Range
MA: GBX 25.75
52-Week Range
Now: GBX 27.90
Volume545,252 shs
Average VolumeN/A
Market Capitalization£105.16 million
P/E RatioN/A
Dividend YieldN/A
Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD). Its pipeline products include Flixotide, Seretide, and Flovent for asthma; and various novel specialty for COPD treatments, such as Duaklir, Spiriva, Novel LABA/LAMA formulation, and novel COPD therapy formulation. The company has a collaboration agreement with AstraZeneca to promote Tudorza and for COPD treatment, and has the United States commercial rights to COPD therapy Duaklir. It markets its products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners in China, Japan, Europe, and internationally. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.
Read More
Circassia Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone44 1865 405 560



Sales & Book Value

Annual Sales£62.40 million
Cash FlowGBX 7.30 per share
Book ValueGBX 22.60 per share



Market Cap£105.16 million
Next Earnings DateN/A
GBX 27.90
-0.03 (-0.11 %)
(As of 08/13/2020 04:06 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CIR News and Ratings via Email

Sign-up to receive the latest news and ratings for CIR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Circassia Pharmaceuticals (LON:CIR) Frequently Asked Questions

How has Circassia Pharmaceuticals' stock price been impacted by COVID-19?

Circassia Pharmaceuticals' stock was trading at GBX 19.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CIR shares have increased by 42.0% and is now trading at GBX 27.90.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Circassia Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Circassia Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Circassia Pharmaceuticals

What price target have analysts set for CIR?

1 analysts have issued 12 month price objectives for Circassia Pharmaceuticals' shares. Their forecasts range from GBX 70 to GBX 80. On average, they expect Circassia Pharmaceuticals' share price to reach GBX 73.33 in the next year. This suggests a possible upside of 162.8% from the stock's current price.
View analysts' price targets for Circassia Pharmaceuticals

Has Circassia Pharmaceuticals been receiving favorable news coverage?

Media stories about CIR stock have trended extremely negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Circassia Pharmaceuticals earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Circassia Pharmaceuticals

Who are some of Circassia Pharmaceuticals' key competitors?

What other stocks do shareholders of Circassia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Circassia Pharmaceuticals investors own include Enquest (ENQ), BOOHOO GRP PLC/ADR (BHOOY), Cummins (CMI), FutureFuel (FF), Trade Desk (TTD), Ascential (ASCL), H&T Group (HAT), Howden Joinery Group (HWDN), NMC Health (NMC) and Oxford BioMedica (OXB).

Who are Circassia Pharmaceuticals' key executives?

Circassia Pharmaceuticals' management team includes the following people:
  • Mr. Steven Charles Andrew Harris, Co-Founder, CEO & Director (Age 52)
  • Mr. Julien Cotta, CFO, Company Sec. & Director (Age 55)
  • Dr. Roderick Peter Hafner, Sr. VP of R&D and Director (Age 53)
  • Ms. Nina Kataria, Sr. VP Global HR
  • Mr. David L. Acheson, Sr. VP of US Commercial

What is Circassia Pharmaceuticals' stock symbol?

Circassia Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "CIR."

How do I buy shares of Circassia Pharmaceuticals?

Shares of CIR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Circassia Pharmaceuticals' stock price today?

One share of CIR stock can currently be purchased for approximately GBX 27.90.

How big of a company is Circassia Pharmaceuticals?

Circassia Pharmaceuticals has a market capitalization of £105.16 million and generates £62.40 million in revenue each year. Circassia Pharmaceuticals employs 400 workers across the globe.

What is Circassia Pharmaceuticals' official website?

The official website for Circassia Pharmaceuticals is www.circassia.co.uk.

How can I contact Circassia Pharmaceuticals?

The company can be reached via phone at 44 1865 405 560.

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.